An archaeal histone-like protein as an efficient DNA carrier in gene transfer

被引:10
作者
Weng, L
Liu, D
Li, Y
Cao, SG
Feng, Y [1 ]
机构
[1] Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China
[2] Changchun Inst Biol Prod, Changchun 130061, Peoples R China
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2004年 / 1702卷 / 02期
关键词
gel retardation assay; transfection; Histone-like protein; lipofectamine; serum resistance;
D O I
10.1016/j.bbapap.2004.08.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HPhA, a recombinant histone-like protein from Pyrococcus horikoshii OT3 strain, has compacting activity with DNA as previously reported. The extreme stability and DNA packaging activity of the HPhA make it a candidate as a DNA carrier. Here, the plasmid DNA-HPhA complexes were fully characterized by gel retardation assay and DNase resistance assay. It was further proved that HPhA has in vitro DNA transfection activity. HPhA-mediated transfection efficiency was dependent on the mass ratio of HPhA to DNA, the incubation time and the presence of calcium. A protocol for HPhA-mediated transfection in vitro was established to improve transfection efficiency. The optimal mass ratio of HPhA to DNA was 6: 1, and the incubation time required for the DNA-HPhA complex to be in contact with the cell was 4 h. In addition, the presence of 2 mM CaCl2 in the cell culture medium was required for efficient transfection. Serum did not show inhibition of HPhA-mediated transfection. Most importantly, the cytotoxicity of HPhA is lower than that of commonly used cationic liposome-based gene delivery systems, and HPhA-mediated transfection in NIH 3T3, HEK 293, HL-7702, HepG2 and Cos 7 cell lines in vitro has a higher efficiency and reproducibility. These results demonstrate that the HPhA is a new, potentially widely applicable and highly efficient gene carrier. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 27 条
[1]  
Audouy S, 2000, J GENE MED, V2, P465, DOI 10.1002/1521-2254(200011/12)2:6<465::AID-JGM141>3.0.CO
[2]  
2-Z
[3]   Gene therapy of human disease [J].
Balicki, D ;
Beutler, E .
MEDICINE, 2002, 81 (01) :69-86
[4]   Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection [J].
Barry, ME ;
Pinto-González, D ;
Orson, FM ;
McKenzie, GJ ;
Petry, GR ;
Barry, MA .
HUMAN GENE THERAPY, 1999, 10 (15) :2461-2480
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]   A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA [J].
Brandén, LJ ;
Mohamed, AJ ;
Smith, CIE .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :784-787
[7]   Approaches to gene therapy for human immunodeficiency virus infection [J].
Buchschacher, GL ;
Wong-Staal, F .
HUMAN GENE THERAPY, 2001, 12 (09) :1013-1019
[8]   Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors [J].
Buvoli, M ;
Langer, SJ ;
Bialik, S ;
Leinwand, LA .
GENE THERAPY, 2002, 9 (03) :227-231
[9]  
CAPLEN NJ, 1995, GENE THER, V2, P603
[10]  
Chang LJ, 2001, CURR OPIN MOL THER, V3, P468